Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Sanofi to buy cancer immunotherapy biotech for $1B
Sanofi to buy cancer immunotherapy biotech for $1B
Sanofi will pay $1 billion to acquire privately held Amunix Pharmaceuticals and its cancer immunotherapy technology in a deal announced Tuesday by the French pharmaceutical company. ...
Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
Vivoryon Therapeutics N.V., a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, tod...
FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention
FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pou...
Omicron sweeps across nation, now 73% of new US COVID cases
Omicron sweeps across nation, now 73% of new US COVID cases
Omicron has raced ahead of other variants and is now the dominant version of the coronavirus in the U.S., accounting for 73% of new infections last week, federal health officials said Monday. ...
Biogen cuts the price tag on its Alzheimer’s drug in half
Biogen cuts the price tag on its Alzheimer’s drug in half
Biogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually. ...
Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumab
Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumab
The FDA has approved AstraZeneca and Amgen’s severe asthma hope tezepelumab, exonerating the drugmakers’ decision to press ahead with a regulatory filing despite a failed phase 3 trial. ...
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors
The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced by the data submitted for the drug. ...
Novavax's COVID vaccine becomes the fifth jab to be approved for use in the EU
Novavax's COVID vaccine becomes the fifth jab to be approved for use in the EU

It was given the green light by the bloc's drugs regulator, the European Medicines Agency (EMA), on Monday.

Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee
Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee
Xalud Therapeutics, a clinical-stage biotechnology company developing DNA delivery therapies using a non-viral platform, announced today that the United States Food and Drug Administration (FDA) ha...
Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, announced today that the U.S. Food and D...
FDA Approves Tarpeyo (budesonide) to Reduce Proteinuria in IgA Nephropathy
FDA Approves Tarpeyo (budesonide) to Reduce Proteinuria in IgA Nephropathy
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release c...
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
AbbVie today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand